|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder | |||
| 化学式 | C25H23ClN2O3S2 |
||||||
| 分子量 | 499.04 | CAS No. | 2003234-63-5 | ||||
| Solubility (25°C)* | 体外 | DMSO | 100 mg/mL (200.38 mM) | ||||
| Water | Insoluble | ||||||
| Ethanol | Insoluble | ||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||
| 製品説明 | (R)-GNE-140 is an inhibitory agent for LDHA, LDHB, and LDHC, with IC50 values of 3 nM and 5 nM for LDHA and LDHB, respectively. (R)-GNE-140 is 18 times more potent than its S isomer. |
|---|---|
| in vitro | (R)-GNE-140 inhibits proliferation in 37 of 347 cancer cell lines tested at a potency cut off of 5 μM. This compound exhibits inhibition with two chondrosarcoma (bone) cancer cell lines that harbored IDH1 mutations (IC50 = 0.8μM). This chemical has submicromolar MiaPaca2 potency and inhibits proliferation in 11% of cancer cell lines in a broad panel. [1] |
| in vivo | (R)-GNE-140 presents a low Clp, and also had high bioavailability when dosed orally at 5 mg/kg to mice. At higher oral doses, ranging from 50 to 200 mg/kg, this compound displays greater in vivo exposure.[1] |
| 細胞アッセイ | 細胞株 | 105KC,JJ012,143B,G84,1321N1,ONS-76,G22,G140,G96,HCC1143,CAL-120,Hs 578T,SISO,SKG-II,HCT-15,KYSE-520,KMRC-1,SNU-475,SNU-423,HT-1080,NCI-H1437,NCI-H1339,LXF-289,MCAS,PA-1,Hs 38.T,59M,MIA PaCa-2,SW 1990,PSN1,GR-M,Hs 746T,MKN-74,S-117,FTC-238,B-CPAP,HEC-265 cell lines |
|---|---|---|
| 濃度 | 6 pt dose titration scheme | |
| 反応時間 | 72 h | |
| 実験の流れ | Cells are plated using optimal seeding densities in 384-well plates using RPMI, 5% FBS, 100 ug/ml penicillin, 100 units/ml streptomycin. Optimal seeding densities are established for each cell line in order to reach 75-80% confluence at the end of the assay. The following day, cells are treated with (R)-GNE-140 using a 6 pt dose titration scheme. After 72 hours, cell viability is assessed using the CellTiter-Glo® Luminescence Cell Viability assay. Absolute inhibitory concentration (IC) values are calculated using four-parameter logistic curve fitting. |
|
| 動物実験 | 動物モデル | Female CD-1 mice |
| 投薬量 | IV: 1.0 mg/kg; Oral: 5,50,100,200 mg/kg | |
| 投与方法 | IV / Oral |
|
| Pharmacologic LDH inhibition redirects intratumoral glucose uptake and improves antitumor immunity in solid tumor models [ J Clin Invest, 2024, 134(17)e177606] | PubMed: 39225102 |
| DNAJC12 downregulation induces neuroblastoma progression via increased histone H4K5 lactylation [ J Mol Cell Biol, 2024, mjae056] | PubMed: 39716470 |
| Lactate promotes myogenesis via activating H3K9 lactylation-dependent up-regulation of Neu2 expression [ J Cachexia Sarcopenia Muscle, 2023, 10.1002/jcsm.13363] | PubMed: 37919243 |
| Host T cell dedifferentiation effects drive HIV-1 latency stability [ J Virol, 2022, jvi0197421] | PubMed: 35019721 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。